The future of metabolic management isn't just about less frequent dosing, its about ensuring a comprehensive, high-quality patient experience throughout the entire journey
The study found that cilastatin was associated with a 74% lower risk of AKI in randomized controlled trials (3 studies, 245 patients), and a 46% lower risk in observational studies (4 studies, 6,321 patients)
Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation
Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist (GLP-1ra) that can be taken any time of the day without restrictions on food and water intake
While pharmaceutical doses of GLP-1 can force appetite suppression (which is why semaglutide often causes nausea), GIP activates the pathway these neurons are designed for
[12, 13] Taken together, these findings establish GLP-1 receptor agonists as among the most effective medical therapies for both diabetes and obesity, driving their rapid and widespread use